Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Bioengineered Protein Drugs Market Size Changed, over the years?

In recent years, the market size for bioengineered protein drugs has seen substantial growth. It is set to expand from $406.39 billion in 2024 to $439.29 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.1%. Factors contributing to growth during the historic period include a heightened understanding of diseases, regulatory sanctioning, an increase in chronic illnesses, collaborations and partnerships, and market expansion.

How Much Will the Bioengineered Protein Drugs Market Be Worth in 2029?

The market size of bioengineered protein drugs is predicted to significantly increase in the coming years, with an expected value of $604.42 billion in 2029 and a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the forecast period include the trend towards personalized medicine, growth in therapeutic applications, emerging markets, a focus on orphan diseases, and the development of healthcare infrastructure. The forecast period is also expected to witness key trends like advances in protein engineering, a heightened emphasis on monoclonal antibodies, personalized and targeted therapies, the rise of next-generation biologics, and optimization of manufacturing processes.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10180&type=smp

Which is the Largest Company in the Bioengineered Protein Drugs Market?

Major companies operating in the bioengineered protein drugs market include Abbvie Inc., Amgen Inc., Astrazeneca PLC, Bayer HealthCare Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Novo Nordisk A/S, Sanofi S.A., Grifols S.A., Adma Biologics Inc., CSL Limited, Abbott Laboratories, Baxter International Inc., Fresenius Kabi AG, Merck & Co. Inc., Pfizer Inc., Biogen Inc., Bristol-Myers Squibb Company, Genentech Inc., Lonza Group AG, MedImmune LLC, Regeneron Pharmaceuticals Inc., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Shanghai United Cell Biotechnology Co. Ltd., Panacea Biotec Ltd.

What Are the Main Market Drivers in the Bioengineered Protein Drugs Industry?

The growing incidence of chronic diseases is anticipated to boost the expansion of the bioengineered protein drug market in the future. Chronic illnesses are those which individuals grapple with for over a year, demand continuous medical attention, and limit daily physical activities. Bioengineered protein drugs treat these chronic conditions with customized protein treatment strategies particularly in cancer treatments and regenerative medicine, utilizing combination and logical tactics. For example, the 2022 Highlights by the World Health Organization (WHO), a Switzerland-rooted intergovernmental health body, showed 41 million deaths in September 2022, translating to 74% of total global deaths from noncommunicable diseases (NCDs) or chronic illnesses in a year were 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Thus, the escalating chronic disease prevalence is propelling bioengineered protein drugs’ market growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10180&type=smp

How Is the Bioengineered Protein Drugs Market Segments Structured?

The bioengineered protein drugs market covered in this report is segmented –

1) By Drug Type: Recombinant Protein, Vaccine, Peptide Antibiotics, Therapeutic Enzymes, Other Drug Type

2) By Technology: Bioreactors, Fractionation, Genetically Modified Organisms, Genetic Engineering, Pharming, Cell Culture, Microbial Cell Fermentation, Other Technology

3) By Application: Autoimmune, Heart, Congenital, Infectious Diseases, Cancer, Diabetes, Arthritis, Other Application

4) By End User: Pharmaceutical, Contract Research Organizations, Research Institutes, Biotechnology Companies

Subsegments:

1) By Recombinant Protein: Monoclonal Antibodies, Hormones, Cytokines

2) By Vaccine: Recombinant Vaccines, DNA Vaccines

3) By Peptide Antibiotics: Lipopeptide Antibiotics, Glycopeptide Antibiotics

4) By Therapeutic Enzymes: Enzyme Replacement Therapies, Biosimilar Enzymes

5) By Other Drug Type: Fusion Proteins, Antibody-Drug Conjugates (ADCs)

What Strategic Trends Are Transforming the Bioengineered Protein Drugs Market?

In the bioengineered protein drug market, premier businesses are leveraging strategic partnerships to supply essential bioengineered protein drugs to corporations and government entities. These strategic partnerships allow companies to utilize each other’s unique abilities and resources for mutual benefits and success. For example, Future Fields, a biotechnology company from Canada, formed a strategic partnership with Jenthera Therapeutics, another Canadian biotechnology firm specializing in innovative therapies for rare and challenging diseases, in June 2023. They aim to create an innovative cancer-fighting protein using the EntoEngine platform of Future Fields, enabling cost-effective and sustainable mass production.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bioengineered-protein-drugs-global-market-report

Which Global Regions Offer the Highest Growth in the Bioengineered Protein Drugs Market?

North America was the largest region in the bioengineered protein drugs market in 2024. The regions covered in the bioengineered protein drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10180

This Report Delivers Insight On:

1. How big is the bioengineered protein drugs market, and how is it changing globally?

2. Who are the major companies in the bioengineered protein drugs market, and how are they performing?

3. What are the key opportunities and risks in the bioengineered protein drugs market right now?

4. Which products or customer segments are growing the most in the bioengineered protein drugs market?

5. What factors are helping or slowing down the growth of the bioengineered protein drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model